Article Text

Download PDFPDF
Letter
Influence of clarithromycin on the bactericidal effect of amoxicillin in patients infected with clarithromycin-resistant strains of H. pylori
  1. Takahisa Furuta1,
  2. Mihoko Yamade2,
  3. Takuma Kagami2,
  4. Takahiro Suzuki2,
  5. Tomohiro Higuchi2,
  6. Shinya Tani3,
  7. Yasushi Hamaya2,
  8. Moriya Iwaizumi4,
  9. Hiroaki Miyajima2,
  10. Kazuo Umemura5,
  11. Satoshi Osawa3,
  12. Ken Sugimoto2
  1. 1 Center for Clinical Research, Hamamatsu University School of Medicine, Hamamatsu, Japan
  2. 2 First Department of Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan
  3. 3 Department of Endoscopic and Photodynamic Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan
  4. 4 Department of Clinical Laboratory Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan
  5. 5 Department of Pharmacology, Hamamatsu University School of Medicine, Hamamatsu, Japan
  1. Correspondence to Dr Takahisa Furuta, Center for Clinical Research, Hamamatsu University School of Medicine, Hamamatsu 4313192, Japan; furuta{at}hama-med.ac.jp

Statistics from Altmetric.com

We read the manuscript written by Suzuki et al 1 with interest. They reported that the eradication rate of Helicobacter pylori attained by the dual therapy with vonoprazan and amoxicillin (VA-Dual) was almost the same as that attained by the triple therapy with vonoprazan, amoxicillin and clarithromycin (VAC-Triple), as previously reported by us.2 The most interesting point in this paper was that the VA-Dual therapy was superior to the VAC-Triple therapy in eradicating the clarithromycin-resistant strains of H. pylori. In this regard, the authors consider the possibilities of a type I error, the difference in the proportion of amoxicillin-resistant strains, and the excessive inhibition of gastric acid secretion …

View Full Text

Footnotes

  • Twitter @moriyaibonheur

  • Contributors All authors have checked the manuscript.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient consent for publication Not required.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.